rhenium-186 hedp has been researched along with Bone Neoplasms in 58 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 8 (13.79) | 18.2507 |
| 2000's | 33 (56.90) | 29.6817 |
| 2010's | 17 (29.31) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Beeker, A; Bloemendal, HJ; de Klerk, JMH; Hoekstra, OS; Jonker, MA; Los, M; O'Sullivan, JM; Oprea-Lager, DE; van den Berg, HP; van den Eertwegh, AJM; van Dodewaard-de Jong, JM; Verheul, HMW | 1 |
| Banerjee, S; Dash, A; Kameswaran, M; Kumar, C; Mallia, MB; Sarma, HD; Sharma, R | 1 |
| Deilami-Nezhad, L; Moghaddam-Banaem, L; Sadeghi, M | 1 |
| Chittenden, SJ; Dearnaley, DP; Denis-Bacelar, AM; Divoli, A; Flux, GD; Johnson, B; McCready, VR; O'Sullivan, JM | 1 |
| Amoui, M; Asli, IN; Assadi, M; Kalantari, BA; Mirzaee, HR; Pirayesh, E; Rakhsha, A; Shafiei, B; Tabei, F | 1 |
| Beekman, FJ; Bloemendal, HJ; Breukels, OB; de Graaf, H; de Klerk, JM; Hendrikse, NH; Lange, R; Malingré, MM; Rummenie, RG; ter Heine, R; van den Berg, L; van der Westerlaken, MM; Wakker, AM; Wielders, JP | 1 |
| Bloemendal, HJ; de Klerk, JM; Hoekstra, OS; Hooft, L; Jong, JM; Oprea-Lager, DE; van den Eertwegh, AJ; Verheul, HM | 1 |
| Aswathy, KK; Banerjee, S; Kalarikal, R; Kamaleshwaran, KK; Kameswaran, M; Mallia, MB; Shinto, AS | 1 |
| Bloemendal, HJ; de Klerk, JM; Hendrikse, NH; Kooistra, A; Lange, R; Overbeek, F; Pasker-de Jong, PC; Rodenburg, CJ; Ter Heine, R; van den Berk, AM | 1 |
| Chittenden, SJ; Dearnaley, DP; Denis-Bacelar, AM; Divoli, A; Du, Y; Flux, GD; Johnson, B; McCready, VR; O'Sullivan, JM | 1 |
| Bloemendal, HJ; de Klerk, JM; Geldof, AA; Hendrikse, NH; Lange, R; Paap, M; ter Heine, R; Tromp, AM; van Wieringen, WN | 1 |
| Baziotis, N; Limouris, GS; Zafeirakis, A; Zissimopoulos, A | 2 |
| Chen, S; Cheng, A; Dong, M; Yin, D; Zhang, Y | 1 |
| Alsharif, A; Boni, G; Borsò, E; Chiacchio, S; Greco, C; Grosso, M; Lorenzoni, A; Manca, G; Mariani, G; Mazzarri, S; Nyakale, N; Volterrani, D | 1 |
| Bloemendal, HJ; de Haas, MJ; de Klerk, JM; O'Sullivan, JM; van Bezooijen, BP; van Dodewaard-de Jong, JM; Wilson, RH | 1 |
| Andris, A; Biersack, HJ; Bucerius, J; Ezziddin, S; Guhlke, S; Knapp, FF; Palmedo, H; Rogenhofer, S; von Mallek, D | 1 |
| Aras, G; Gümüş-Akay, G; Ibiş, E; Köroğlu, R; Küçük, O; Ozkal-Baydin, P; Rüstemoğlu, A; Sunguroğlu, A; Varol, N; Yüksel, S | 1 |
| Silberstein, EB; Taylor, AT | 1 |
| Buffa, FM; Chittenden, SJ; Dearnaley, DP; Flux, GD; Guy, MJ; McCready, VR; O'Sullivan, JM | 1 |
| Franke, WG; Hliscs, R; Knapp, FF; Kropp, J; Liepe, K; Runge, R | 1 |
| Albers, P; Biersack, HJ; Ezziddin, S; Fimmers, R; Guhlke, S; Joe, A; Knapp, FF; Manka-Waluch, A; Palmedo, H; Reinhardt, M; Roedel, R; Schmidt-Wolf, IG | 1 |
| Kotzerke, J; Kropp, J; Liepe, K; Runge, R | 1 |
| Bandurski, T; Derejko, M; Romanowicz, G; Scheffler, J | 1 |
| Endo, K; Li, S; Liu, J; Tanada, S; Tian, M; Zhang, H | 1 |
| de Klerk, JM; Lam, MG; van Rijk, PP | 1 |
| Kotzerke, J; Liepe, K; Runge, R | 1 |
| Anagnostopoulou, US; Datseris, EI; Leondi, AH; Leontopoulou, SA; Papadaki, EK; Rapti, AS; Souvatzoglou, MA; Zerva, CJ | 1 |
| Binnie, D; Dearnaley, D; Divoli, A; Flux, G; McCready, VR | 1 |
| Chen, SX; DU, JQ; Jiang, NY; Liang, JG; Liu, XG; Lu, XP | 1 |
| Buffa, FM; Coffey, J; Cook, G; Dearnaley, DP; Flux, G; Horwich, A; Huddart, RA; Johnson, B; McCready, VR; Norman, AR; O'Sullivan, JM; Parker, CC; Treleaven, J | 1 |
| Bergomi, S; Maini, CL; Romano, L; Sciuto, R | 1 |
| Antonini, N; Hoefnagel, CA; Horenblas, S; Valdes Olmos, RA; van der Poel, HG | 1 |
| Bomanji, J; Cassoni, A; Ell, PJ; Groves, A; Kayani, I; Nagabhushan, N; Syed, R; Waddington, W | 1 |
| Benassi, M; D'Andrea, M; Maini, CL; Pasqualoni, R; Sciuto, R; Strigari, L | 1 |
| Kotzerke, J; Liepe, K | 1 |
| de Klerk, JM; Lam, MG; van Rijk, PP; Zonnenberg, BA | 1 |
| El-Mabhouh, AA; Mercer, JR | 1 |
| Koutsikos, J; Leondi, A | 1 |
| Bender, H; Biersack, HJ; Dierke-Dzierzon, C; Grünwald, F; Mallmann, P; Palmedo, H; Reichmann, K; Schomburg, A; Schöneich, G; Zamorra, P | 1 |
| Botha, JM; Doman, MJ; Goedhals, L; Lötter, MG; Marais, J; Naudé, H; Otto, AC; Roodt, A; van Aswegen, A | 1 |
| Biersack, HJ; Dierke-Dzierzon, C; Müller, SC; Palmedo, H; Schoeneich, G | 1 |
| Holle, LH; Humke, U; Kirsch, CM; Oberhausen, E; Trampert, L; Ziegler, M | 1 |
| Blijham, GH; de Klerk, JM; Han, SH; Quirijnen, JM; van Dijk, A; van het Schip, AD; van Rijk, PP; Zonneberg, BA | 1 |
| Curley, T; Daghighian, F; Goldsmith, SJ; Graham, MC; Larson, SM; Liu, GB; Scher, HI; Yeh, SD | 1 |
| Hsieh, BT; Hsieh, JF; Lin, WY; Ting, G; Tsai, SC; Wang, SJ | 1 |
| Bohuslavizki, KH; Klutmann, S | 1 |
| Franke, WG; Grüning, T; Hliscs, R; Knapp, FF; Koch, R; Kropp, J; Liepe, K; Runge, R | 1 |
| Aras, G; Baltaci, S; Bedük, Y; Canakci, N; Ibiş, E; Küçük, NO; Ozalp, G; Soylu, A | 1 |
| Carpentier, P; Caty, A; Depreux, P; Kolesnikov-Gauthier, H; Sulman, C; Vennin, P | 1 |
| Franke, WG; Hliscs, R; Koch, R; Kropp, J; Liepe, K; Runge, R | 1 |
| Franke, WG; Hliscs, R; Kropp, J; Liepe, K | 1 |
| Brenner, W; Henze, E; Kampen, AM; Kampen, WU | 1 |
| Bergomi, S; Festa, A; Maini, CL; Pasqualoni, R; Rea, S; Sciuto, R; Semprebene, A | 1 |
| Bestagno, M; Cittanti, C; Colamussi, P; Dafermou, A; Giganti, M; Piffanelli, A | 1 |
| Banerjee, S; Chaudhari, PR; Kothari, K; Pillai, MR; Samuel, G; Sarma, HD; Unni, PR; Unnikrishnan, TP | 1 |
| Li, S; Liu, J; Tian, M; Wang, J; Zhang, H; Zheng, X | 1 |
| Al-Deen, A; Buffa, FM; Chittenden, S; Cook, G; Dearnaley, DP; Flux, G; Gadd, J; Guy, M; Horwich, A; Huddart, RA; McCready, VR; Norman, AR; O'Sullivan, JM; Pomeroy, K; Treleaven, J | 1 |
6 review(s) available for rhenium-186 hedp and Bone Neoplasms
| Article | Year |
|---|---|
Radiopharmaceuticals for Palliation of Bone Pain in Patients with Castration-resistant Prostate Cancer Metastatic to Bone: A Systematic Review.
Topics: Antineoplastic Agents; Bone Neoplasms; Cancer Pain; Etidronic Acid; Humans; Male; Organometallic Compounds; Organophosphorus Compounds; Palliative Care; Prospective Studies; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radiopharmaceuticals; Radium; Randomized Controlled Trials as Topic; Strontium; Strontium Radioisotopes | 2016 |
Radionuclide therapy and integrated protocols for bone metastases.
Topics: Bone Neoplasms; Combined Modality Therapy; Diphosphonates; Drug Therapy, Combination; Etidronic Acid; Humans; Organometallic Compounds; Organophosphorus Compounds; Pain; Palliative Care; Patient Selection; Radioimmunotherapy; Radiopharmaceuticals; Technetium Tc 99m Medronate; Treatment Outcome | 2011 |
Application of rhenium-188 HEDP in bone metastases therapy.
Topics: Bone Neoplasms; Etidronic Acid; Humans; Leukopenia; Organometallic Compounds; Pain; Palliative Care; Practice Patterns, Physicians'; Radiopharmaceuticals; Rhenium; Thrombocytopenia; Treatment Outcome | 2003 |
186Re-HEDP for metastatic bone pain in breast cancer patients.
Topics: Bone Neoplasms; Breast Neoplasms; Dose-Response Relationship, Radiation; Etidronic Acid; Female; Humans; Maximum Tolerated Dose; Organometallic Compounds; Pain; Palliative Care; Radiation Injuries; Radioimmunotherapy; Radiopharmaceuticals; Radiotherapy Dosage; Rhenium; Treatment Outcome | 2004 |
Radionuclide therapy with bone seeking radionuclides in palliation of painful bone metastases.
Topics: Bone Neoplasms; Etidronic Acid; Humans; Organometallic Compounds; Organophosphorus Compounds; Pain; Palliative Care; Radionuclide Imaging; Strontium | 2003 |
Bone seeking radiopharmaceuticals for palliation of pain in cancer patients with osseous metastases.
Topics: Bone Neoplasms; Clinical Trials as Topic; Etidronic Acid; Humans; Medical Oncology; Models, Chemical; Neoplasm Metastasis; Neoplasms; Organometallic Compounds; Organophosphorus Compounds; Pain; Radiometry; Radionuclide Imaging; Radiopharmaceuticals; Strontium; Treatment Outcome | 2007 |
23 trial(s) available for rhenium-186 hedp and Bone Neoplasms
| Article | Year |
|---|---|
A randomised, phase II study of repeated rhenium-188-HEDP combined with docetaxel and prednisone versus docetaxel and prednisone alone in castration-resistant prostate cancer (CRPC) metastatic to bone; the Taxium II trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Disease-Free Survival; Docetaxel; Etidronic Acid; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Organometallic Compounds; Prednisone; Prostatic Neoplasms, Castration-Resistant; Taxoids | 2017 |
Phase 2 study of a high dose of 186Re-HEDP for bone pain palliation in patients with widespread skeletal metastases.
Topics: Adult; Aged; Bone Neoplasms; Etidronic Acid; Female; Humans; Male; Middle Aged; Organometallic Compounds; Pain; Pain Management; Palliative Care; Radiation Dosage | 2013 |
Treatment of painful bone metastases in prostate and breast cancer patients with the therapeutic radiopharmaceutical rhenium-188-HEDP. Clinical benefit in a real-world study.
Topics: Aged; Bone Neoplasms; Breast Neoplasms; Cancer Pain; Comorbidity; Etidronic Acid; Female; Humans; Male; Netherlands; Organometallic Compounds; Palliative Care; Prevalence; Prostatic Neoplasms; Quality of Life; Radiopharmaceuticals; Risk Factors; Treatment Outcome | 2016 |
The tolerance and therapeutic efficacy of rhenium-188 hydroxyethylidene diphosphonate in advanced cancer patients with painful osseous metastases.
Topics: Blood Cell Count; Bone Neoplasms; Electrocardiography; Etidronic Acid; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasms; Organometallic Compounds; Pain; Pain Measurement; Palliative Care | 2011 |
A phase I study of combined docetaxel and repeated high activity 186Re-HEDP in castration-resistant prostate cancer (CRPC) metastatic to bone (the TAXIUM trial).
Topics: Aged; Bone Neoplasms; Chemoradiotherapy; Docetaxel; Etidronic Acid; Humans; Male; Middle Aged; Orchiectomy; Organometallic Compounds; Prostatic Neoplasms; Radiotherapy Dosage; Taxoids; Treatment Outcome | 2011 |
A model-based method for the prediction of whole-body absorbed dose and bone marrow toxicity for 186Re-HEDP treatment of skeletal metastases from prostate cancer.
Topics: Body Burden; Bone Marrow; Bone Neoplasms; Computer Simulation; Etidronic Acid; Humans; Injections, Intravenous; Male; Models, Biological; Organometallic Compounds; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms; Radiometry; Radionuclide Imaging; Radiopharmaceuticals; Radiotherapy Planning, Computer-Assisted; Relative Biological Effectiveness; Rhenium; Statistics as Topic; Treatment Outcome; Whole-Body Counting | 2003 |
Dosimetry of 188Re-hydroxyethylidene diphosphonate in human prostate cancer skeletal metastases.
Topics: Aged; Aged, 80 and over; Body Burden; Bone Marrow; Bone Neoplasms; Etidronic Acid; Half-Life; Humans; Injections, Intravenous; Kidney; Male; Metabolic Clearance Rate; Middle Aged; Organometallic Compounds; Prostatic Neoplasms; Radiation Dosage; Radiometry; Rhenium; Tissue Distribution; Urinary Bladder; Whole-Body Counting | 2003 |
Repeated bone-targeted therapy for hormone-refractory prostate carcinoma: tandomized phase II trial with the new, high-energy radiopharmaceutical rhenium-188 hydroxyethylidenediphosphonate.
Topics: Aged; Bone Neoplasms; Disease Progression; Dose-Response Relationship, Radiation; Etidronic Acid; Humans; Male; Organometallic Compounds; Pain Measurement; Pain, Intractable; Palliative Care; Prospective Studies; Prostatic Neoplasms; Radiotherapy Dosage; Rhenium; Treatment Outcome | 2003 |
Therapeutic efficiency of rhenium-188-HEDP in human prostate cancer skeletal metastases.
Topics: Aged; Aged, 80 and over; Blood Cell Count; Bone Neoplasms; Etidronic Acid; Humans; Male; Middle Aged; Neoplasm Staging; Organometallic Compounds; Pain; Pain Measurement; Prostatic Neoplasms; Radioisotopes; Radionuclide Imaging; Rhenium; Treatment Outcome | 2003 |
The benefit of bone-seeking radiopharmaceuticals in the treatment of metastatic bone pain.
Topics: Aged; Aged, 80 and over; Analgesics, Non-Narcotic; Bone Neoplasms; Breast Neoplasms; Etidronic Acid; Female; Humans; Karnofsky Performance Status; Male; Middle Aged; Organometallic Compounds; Organophosphorus Compounds; Pain; Palliative Care; Prostatic Neoplasms; Radioisotopes; Surveys and Questionnaires; Time Factors; Treatment Outcome | 2005 |
Palliative treatment of painful disseminated bone metastases with 186Rhenium-HEDP in patients with lung cancer.
Topics: Bone Neoplasms; Carcinoma; Etidronic Acid; Female; Humans; Lung Neoplasms; Male; Middle Aged; Organometallic Compounds; Pain; Palliative Care; Patient Selection; Radiopharmaceuticals; Treatment Outcome | 2004 |
[Clinical value of combined therapy with 188Re-HEDP and pamidronate in breast cancer with bone metastasis].
Topics: Adult; Aged; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Carcinoembryonic Antigen; Combined Modality Therapy; Diphosphonates; Etidronic Acid; Female; Follow-Up Studies; Humans; Middle Aged; Organometallic Compounds; Pain; Pain Management; Pamidronate; Radioisotopes; Rhenium | 2005 |
A phase 2 study of high-activity 186Re-HEDP with autologous peripheral blood stem cell transplant in progressive hormone-refractory prostate cancer metastatic to bone.
Topics: Aged; Bone Neoplasms; Combined Modality Therapy; Drug Resistance, Neoplasm; Etidronic Acid; Humans; Male; Middle Aged; Organometallic Compounds; Peripheral Blood Stem Cell Transplantation; Prostatic Neoplasms; Radioisotopes; Radiopharmaceuticals; Rhenium; Transplantation, Autologous | 2006 |
186Re-HEDP in the treatment of patients with inoperable osteosarcoma.
Topics: Adolescent; Adult; Antineoplastic Agents; Body Burden; Bone Neoplasms; Chemotherapy, Adjuvant; Child; Etidronic Acid; Female; Humans; Male; Organometallic Compounds; Osteosarcoma; Radiometry; Radiopharmaceuticals; Radiotherapy Dosage; Radiotherapy, Adjuvant; Treatment Outcome | 2006 |
A comparative study of 188Re-HEDP, 186Re-HEDP, 153Sm-EDTMP and 89Sr in the treatment of painful skeletal metastases.
Topics: Aged; Aged, 80 and over; Analgesics, Non-Narcotic; Bone Marrow; Bone Neoplasms; Breast Neoplasms; Etidronic Acid; Female; Humans; Male; Middle Aged; Organometallic Compounds; Organophosphorus Compounds; Pain; Prospective Studies; Prostatic Neoplasms; Quality of Life; Radiopharmaceuticals; Strontium; Treatment Outcome | 2007 |
[Pain therapy with rhenium-186 HEDP in multiple bone metastases].
Topics: Bone Neoplasms; Breast Neoplasms; Diphosphonates; Etidronic Acid; Female; Humans; Male; Neoplasm Metastasis; Organometallic Compounds; Organotechnetium Compounds; Pain; Palliative Care; Prostatic Neoplasms; Radioisotopes; Rhenium; Time Factors; Tomography, Emission-Computed | 1996 |
Rhenium-186 HEDP: palliative radionuclide therapy of painful bone metastases. Preliminary results.
Topics: Bone Neoplasms; Breast Neoplasms; Etidronic Acid; Female; Humans; Male; Organometallic Compounds; Pain Measurement; Palliative Care; Prostatic Neoplasms; Radioisotopes; Rhenium; Time Factors | 1997 |
186Re-etidronate in breast cancer patients with metastatic bone pain.
Topics: Bone Neoplasms; Breast Neoplasms; Etidronic Acid; Female; Humans; Organometallic Compounds; Pain, Intractable; Palliative Care; Radioisotopes; Rhenium | 1999 |
Rhenium-186-labeled hydroxyethylidene diphosphonate dosimetry and dosing guidelines for the palliation of skeletal metastases from androgen-independent prostate cancer.
Topics: Androgens; Bone Neoplasms; Dose-Response Relationship, Radiation; Etidronic Acid; Humans; Kidney; Male; Metabolic Clearance Rate; Organometallic Compounds; Palliative Care; Prostate-Specific Antigen; Prostatic Neoplasms; Radioisotopes; Radionuclide Imaging; Radiopharmaceuticals; Rhenium; Whole-Body Counting | 1999 |
Evaluation of toxicity and efficacy of 186Re-hydroxyethylidene diphosphonate in patients with painful bone metastases of prostate or breast cancer.
Topics: Adenocarcinoma; Aged; Bone Neoplasms; Breast Neoplasms; Etidronic Acid; Female; Humans; Male; Middle Aged; Organometallic Compounds; Palliative Care; Prostatic Neoplasms; Radioisotopes; Radiopharmaceuticals; Rhenium; Time Factors | 2000 |
[Comparison of rhenium-188, rhenium-186-HEDP and strontium-89 in palliation of painful bone metastases].
Topics: Bone Neoplasms; Breast Neoplasms; Etidronic Acid; Female; Humans; Leukocyte Count; Male; Middle Aged; Organometallic Compounds; Pain; Palliative Care; Platelet Count; Prostatic Neoplasms; Radioisotopes; Rhenium; Strontium Radioisotopes; Tomography, X-Ray Computed | 2000 |
Metastatic bone pain palliation with 89-Sr and 186-Re-HEDP in breast cancer patients.
Topics: Adult; Aged; Bone Neoplasms; Breast Neoplasms; Disease-Free Survival; Etidronic Acid; Female; Humans; Infusions, Intravenous; Karnofsky Performance Status; Middle Aged; Organometallic Compounds; Pain Measurement; Pain, Intractable; Palliative Care; Radionuclide Imaging; Radiopharmaceuticals; Rhenium; Strontium Radioisotopes; Treatment Outcome | 2001 |
High activity Rhenium-186 HEDP with autologous peripheral blood stem cell rescue: a phase I study in progressive hormone refractory prostate cancer metastatic to bone.
Topics: Bone and Bones; Bone Neoplasms; Combined Modality Therapy; Disease Progression; Etidronic Acid; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Organometallic Compounds; Prostate-Specific Antigen; Prostatic Neoplasms; Radionuclide Imaging; Radiotherapy; Recombinant Proteins; Rhenium | 2002 |
29 other study(ies) available for rhenium-186 hedp and Bone Neoplasms
| Article | Year |
|---|---|
In Vitro Evaluation of
Topics: Bone Neoplasms; Cell Culture Techniques; Etidronic Acid; Female; Humans; Male; Organometallic Compounds; Pain; Radiopharmaceuticals | 2017 |
Development of bone seeker radiopharmaceuticals by Scandium-47 and estimation of human absorbed dose.
Topics: Animals; Bone and Bones; Bone Neoplasms; Drug Stability; Etidronic Acid; Humans; In Vitro Techniques; Ligands; Mice; Organometallic Compounds; Organophosphorus Compounds; Radiation Dosage; Radioisotopes; Radiopharmaceuticals; Scandium; Tissue Distribution | 2017 |
Bone lesion absorbed dose profiles in patients with metastatic prostate cancer treated with molecular radiotherapy.
Topics: Bone Neoplasms; Clinical Trials, Phase II as Topic; Etidronic Acid; Humans; Male; Organometallic Compounds; Prostatic Neoplasms; Radiation Dosage; Radiopharmaceuticals; Radiotherapy Dosage; Stem Cell Transplantation; Tissue Distribution; Tomography, Emission-Computed, Single-Photon | 2018 |
Bench to bedside development of GMP grade Rhenium-188-HEDP, a radiopharmaceutical for targeted treatment of painful bone metastases.
Topics: Animals; Bone Neoplasms; Etidronic Acid; Feasibility Studies; Humans; Male; Mice; Organometallic Compounds; Pain; Prostatic Neoplasms; Quality Control; Radionuclide Imaging; Radiopharmaceuticals; Tissue Distribution; Translational Research, Biomedical | 2014 |
A Freeze-Dried Kit for the Preparation of (188)Re-HEDP for Bone Pain Palliation: Preparation and Preliminary Clinical Evaluation.
Topics: Bone Neoplasms; Etidronic Acid; Freeze Drying; Humans; Organometallic Compounds; Pain; Palliative Care; Radiopharmaceuticals; Reagent Kits, Diagnostic | 2016 |
Phase I/II trials of
Topics: Bone Neoplasms; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Etidronic Acid; Humans; Male; Organometallic Compounds; Prostatic Neoplasms, Castration-Resistant; Radiation Dosage; Radiopharmaceuticals; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Survival Analysis; Tomography, Emission-Computed, Single-Photon | 2017 |
Cytotoxic Effects of the Therapeutic Radionuclide Rhenium-188 Combined with Taxanes in Human Prostate Carcinoma Cell Lines.
Topics: Antineoplastic Agents; Bone Neoplasms; Cell Line, Tumor; Chemoradiotherapy; Chemotherapy, Adjuvant; DNA Repair; Docetaxel; Dose-Response Relationship, Drug; Etidronic Acid; Humans; Male; Organometallic Compounds; Prostatic Neoplasms; Radiation-Sensitizing Agents; Radiopharmaceuticals; Taxoids | 2017 |
Management of metastatic bone pain with repeated doses of rhenium 186-HEDP in patients under therapy with zoledronic acid: a safe and additively effective practice.
Topics: Adult; Aged; Aged, 80 and over; Analgesics; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Etidronic Acid; Female; Humans; Imidazoles; Male; Middle Aged; Neoplasm Metastasis; Organometallic Compounds; Pain; Pain Measurement; Prostatic Neoplasms; Treatment Outcome; Zoledronic Acid | 2009 |
Introduction of a new semi-quantitative index with predictive implications in patients with painful osseous metastases after (186)Re-HEDP therapy.
Topics: Adult; Aged; Aged, 80 and over; Bone Neoplasms; Breast Neoplasms; Etidronic Acid; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Organometallic Compounds; Pain; Pain Measurement; Predictive Value of Tests; Prostatic Neoplasms; Radioisotopes; Radiopharmaceuticals; Rhenium | 2011 |
Palliation and survival after repeated (188)Re-HEDP therapy of hormone-refractory bone metastases of prostate cancer: a retrospective analysis.
Topics: Aged; Bone Neoplasms; Drug Resistance, Neoplasm; Etidronic Acid; Follow-Up Studies; Hormones; Humans; Male; Middle Aged; Organometallic Compounds; Palliative Care; Prostatic Neoplasms; Retrospective Studies; Survival Analysis | 2011 |
Potential genotoxic effect of 186Re-HEDP on human lymphocyte cells: in-vitro evaluation with micronucleus-FISH analysis.
Topics: Adult; Bone Neoplasms; Etidronic Acid; Female; Humans; In Situ Hybridization, Fluorescence; Lymphocytes; Male; Middle Aged; Organometallic Compounds; Pain; Radioisotopes; Young Adult | 2012 |
EANM procedure guidelines for treatment of refractory metastatic bone pain.
Topics: Bone Neoplasms; Etidronic Acid; Europe; Humans; Nuclear Medicine; Organometallic Compounds; Organophosphorus Compounds; Pain, Intractable; Palliative Care; Patient Selection; Radiopharmaceuticals; Radiotherapy; Rhenium; Societies, Medical; Treatment Outcome | 2003 |
Rhenium-188-HEDP therapy for the palliation of pain due to osseous metastases in lung cancer patients.
Topics: Adult; Aged; Bone Neoplasms; Dose-Response Relationship, Radiation; Etidronic Acid; Female; Follow-Up Studies; Humans; Leukocyte Count; Lung Neoplasms; Male; Middle Aged; Organometallic Compounds; Pain; Palliative Care; Radionuclide Imaging; Rhenium | 2003 |
The potential use of 99mTc-MDP bone scans to plan high-activity 186Re-HEDP targeted therapy of bony metastases from prostate cancer.
Topics: Bone and Bones; Bone Neoplasms; Etidronic Acid; Humans; Image Processing, Computer-Assisted; Male; Neoplasm Metastasis; Organometallic Compounds; Prostatic Neoplasms; Radioimmunodetection; Radioisotopes; Radiopharmaceuticals; Software; Technetium Tc 99m Medronate; Time Factors; Whole-Body Counting | 2005 |
Serum hemoglobin levels predict response to strontium-89 and rhenium-186-HEDP radionuclide treatment for painful osseous metastases in prostate cancer.
Topics: Aged; Bone Neoplasms; Etidronic Acid; Hemoglobins; Humans; Male; Organometallic Compounds; Pain; Predictive Value of Tests; Prostatic Neoplasms; Radioisotopes; Retrospective Studies; Strontium Radioisotopes | 2006 |
Radiopharmaceutical therapy of bone metastases with 89SrCl2, 186Re-HEDP and 153Sm-EDTMP: a dosimetric study using Monte Carlo simulation.
Topics: Bone Neoplasms; Computer Simulation; Etidronic Acid; Humans; Models, Biological; Monte Carlo Method; Organometallic Compounds; Organophosphorus Compounds; Pain; Palliative Care; Radiometry; Radiopharmaceuticals; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Strontium; Treatment Outcome | 2007 |
188Re-labelled gemcitabine/bisphosphonate (Gem/BP): a multi-functional, bone-specific agent as a potential treatment for bone metastases.
Topics: Animals; Bone and Bones; Bone Neoplasms; Cattle; Combined Modality Therapy; Deoxycytidine; Diphosphonates; Durapatite; Etidronic Acid; Female; Gemcitabine; Humans; In Vitro Techniques; Mice; Mice, Inbred BALB C; Organometallic Compounds; Radioisotopes; Radiopharmaceuticals; Rhenium; Tissue Distribution | 2008 |
Treatment efficacy of combined biphosphonates and 186Re-HEDP treatment in cancer patients with bone metastases.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Combined Modality Therapy; Diphosphonates; Etidronic Acid; Female; Humans; Male; Organometallic Compounds; Organophosphorus Compounds; Prostatic Neoplasms; Radioisotopes; Radiopharmaceuticals; Rhenium | 2008 |
Radiation dose estimates of 186Re-hydroxyethylidene diphosphonate for palliation of metastatic osseous lesions: an animal model study.
Topics: Adult; Animals; Bone and Bones; Bone Neoplasms; Breast Neoplasms; Etidronic Acid; Female; Humans; Kidney; Male; Metabolic Clearance Rate; Organometallic Compounds; Palliative Care; Papio; Prostatic Neoplasms; Radiopharmaceuticals; Rhenium; Tissue Distribution; Urinary Bladder | 1997 |
[Palliative treatment for pain in osseous metastasized prostatic carcinoma with osteotropic rhenium-186 hydroxyethylidene diphosphonate (HEDP)].
Topics: Aged; Aged, 80 and over; Bone Neoplasms; Diphosphonates; Etidronic Acid; Humans; Male; Middle Aged; Organometallic Compounds; Organotechnetium Compounds; Pain; Palliative Care; Prostatic Neoplasms; Radionuclide Imaging; Radiopharmaceuticals; Radiotherapy; Rhenium | 1997 |
Comparison of various rhenium-188-labeled diphosphonates for the treatment of bone metastases.
Topics: Animals; Bone and Bones; Bone Neoplasms; Diphosphonates; Etidronic Acid; Injections, Intravenous; Isotope Labeling; Neoplasm Metastasis; Organometallic Compounds; Rabbits; Radioisotopes; Radionuclide Imaging; Radiopharmaceuticals; Rhenium; Soft Tissue Neoplasms; Tissue Distribution; Whole-Body Counting | 1999 |
[Palliation of bone pain in metastatic prostate carcinoma. Value of radionuclide therapy with rhenium 186 HEDP].
Topics: Aged; Bone Neoplasms; Etidronic Acid; Humans; Male; Organometallic Compounds; Palliative Care; Prostatic Neoplasms; Radioisotopes; Rhenium; Treatment Outcome | 1999 |
Rhenium-188-HEDP in the palliative treatment of bone metastases.
Topics: Aged; Bone Neoplasms; Etidronic Acid; Female; Humans; Male; Middle Aged; Organometallic Compounds; Palliative Care; Radioisotopes; Rhenium | 2000 |
Palliative analgesic effect of Re-186 HEDP in various cancer patients with bone metastases.
Topics: Adult; Aged; Aged, 80 and over; Bone Neoplasms; Breast Neoplasms; Etidronic Acid; Female; Humans; Lung Neoplasms; Male; Middle Aged; Nasopharyngeal Neoplasms; Organometallic Compounds; Pain; Palliative Care; Prostatic Neoplasms; Radiopharmaceuticals; Rectal Neoplasms; Rhenium | 2000 |
Significant reduction of the mass of bone metastasis 1 year after rhenium-186 HEDP pain palliation therapy.
Topics: Bone Neoplasms; Etidronic Acid; Humans; Male; Middle Aged; Organometallic Compounds; Pain; Palliative Care; Prostatic Neoplasms; Radioisotopes; Radionuclide Imaging; Radiopharmaceuticals; Rhenium; Technetium Tc 99m Medronate | 2000 |
Skeletal uptake and soft-tissue retention of 186Re-HEDP and 153Sm-EDTMP in patients with metastatic bone disease.
Topics: Aged; Bone and Bones; Bone Neoplasms; Etidronic Acid; Female; Humans; Male; Middle Aged; Muscle, Skeletal; Organometallic Compounds; Organophosphorus Compounds; Pain Management; Palliative Care; Radionuclide Imaging; Radiopharmaceuticals; Rhenium; Samarium; Thigh; Urinary Bladder | 2001 |
A multicentre observational study of radionuclide therapy in patients with painful bone metastases of prostate cancer.
Topics: Aged; Aged, 80 and over; Bone Neoplasms; Etidronic Acid; Humans; Injections, Intravenous; Male; Middle Aged; Organometallic Compounds; Pain; Pain Measurement; Palliative Care; Prostatic Neoplasms; Radionuclide Imaging; Radiopharmaceuticals; Rhenium; Strontium; Strontium Radioisotopes | 2001 |
186Re-1,4,8,11-tetraaza cyclotetradecyl-1,4,8,11-tetramethylene phosphonic acid: a novel agent for possible use in metastatic bone-pain palliation.
Topics: Analgesics; Animals; Bone Neoplasms; Etidronic Acid; Heterocyclic Compounds, 1-Ring; Injections, Intravenous; Male; Organometallic Compounds; Organophosphonates; Pain; Rabbits; Rats; Rats, Sprague-Dawley; Rhenium; Tissue Distribution | 2001 |
Rhenium-188 HEDP to treat painful bone metastases.
Topics: Bone Neoplasms; Etidronic Acid; Female; Follow-Up Studies; Humans; Leukocyte Count; Male; Middle Aged; Organometallic Compounds; Pain; Pain Management; Palliative Care; Platelet Count; Radionuclide Imaging; Radiopharmaceuticals; Rhenium | 2001 |